Sphingolipid profiling as a biomarker of type 2 diabetes risk: evidence from the MIDUS and PREDIMED studies
Authors' conclusion
Our findings support the potential usefulness of circulating sphingolipid profiles as novel biomarkers for T2D risk. Moreover, this study opens the door for future research on the predictive value and possible protective roles of lactosylceramides in T2D.
Study context
- Population
- American adults from MIDUS cohort (cross-sectional); PREDIMED trial participants (prospective)MIDUS
- Participants
- 2,072 adults
- Exposure
- Sphingolipid scores, extreme quartiles
- Outcome
- Association of sphingolipid species with insulin resistance and T2D prevalence (MIDUS) and T2D incidence (PREDIMED)
- Follow-up
- 3.8 years of median
Methodological detailscase-cohort design nested within the PREDIMED trial, weighted Cox regression with Barlow weights, Sphingolipids measured using LC/MS
- Case-cohort design nested within the PREDIMED trial
- Weighted Cox regression with Barlow weights
- Sphingolipids measured using LC/MS
Main finding
As reported in the abstract
Incident T2D, sphingolipid scores, extreme quartiles
Score 1 HR
0.64 (0.44 to 0.94) (95% CI)
Score 2 HR
0.58
0.40 to 0.85
Score 1 5-year absolute risk difference
9.6% (0.3-20.5%) (95% CI)
Score 2 5-year absolute risk difference
11.4%
1.0–21.6%
Observational data: associations, not effects.
Further findings
Validation of scores · 1 year of follow-up
- Scores validated in PREDIMED with samples obtained after 1 year
Original publication
Sphingolipid profiling as a biomarker of type 2 diabetes risk: evidence from the MIDUS and PREDIMED studies. Cardiovasc Diabetol. Published 18 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →